US FDA okays "compassionate use" of Insmed's Iplex in ALS
This article was originally published in Scrip
Executive Summary
The US FDA has approved "compassionate use" of Insmed's growth treatment Iplex (mecasermin rinfabate [rDNA origin]) for patients with amyotrophic lateral sclerosis (ALS) but is also requiring the company to conduct a clinical trial in this population.